The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRlmediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impairedgastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadianrhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present inventionalso discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cellsinto cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cellsinto vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses aprokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes.

PROKINETICIN 1 RECEPTOR AGONISTS AND THEIR USES

BROGI, Simone;
2012-01-01

Abstract

The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRlmediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impairedgastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadianrhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present inventionalso discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cellsinto cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cellsinto vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses aprokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes.
2012
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/993659
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact